Status:
COMPLETED
Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure
Lead Sponsor:
Novartis
Conditions:
Diastolic Dysfunction, Symptomatic Heart Failure
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure
Eligibility Criteria
Inclusion
- Symptomatic diastolic heart failure
- Breathlessness with physical exertion
Exclusion
- Uncontrolled hypertension
- Asthma, COPD, or abnormal lung function
- History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- Liver, kidney, or pancreas disease
- Allergy to valsartan
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00171106
Start Date
December 1 2002
End Date
February 1 2008
Last Update
November 18 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Centers, Germany
2
Novartis Pharmaceuticals
Basel, Switzerland